Back to search results

Observational Study for a miRNA Signature in Gastrointestinal Cancers

This study is looking for a new way to screen for gastrointestinal (GI) cancers like liver (Hepatocellular Carcinoma), bile duct (Cholangiocarcinoma), pancreas (Pancreatic Ductal Adenocarcinoma), esophagus (Esophageal Squamous Cell Carcinoma), and stomach (Gastric Cancer) cancers. Currently, these cancers are often found late because screening methods are invasive or not sensitive enough. This study will analyze small molecules called microRNAs (miRNAs) in blood samples from people with and without these cancers. The goal is to find a specific pattern of miRNAs that can accurately tell if someone has cancer, which could lead to an easier, non-invasive blood test for early detection. The study aims to enroll 1000 participants.

Study design
This is an observational study involving 1000 participants. It will collect blood samples from people with various gastrointestinal cancers and healthy controls.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint, diagnostic accuracy, is measured at baseline (pre-treatment blood sample).

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07224750

A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer

Recruiting
Not specifiedAges 18+Observational
City of Hope Medical Center
~1,000 participants
Updated 2026-07-07 on ClinicalTrials.gov

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Diagnostic Accuracy of miRNA Panel
Measured over At baseline (pre-treatment blood sample).

Conditions

Hepatocellular Carcinoma (HCC)
Cholangiocarcinoma
Pancreatic Ductal Adenocarcinoma (PDAC)
Esophageal Squamous Cell Carcinoma (ESCC)
Gastric Cancer (GC)
Colorectal Cancer Screening

Explore related trials

CholangiocarcinomaColorectal CarcinomaEsophageal Squamous Cell CarcinomaGastric CarcinomaHepatocellular CarcinomaMalignant Digestive System NeoplasmPancreatic Ductal Adenocarcinoma

Where it's being run

1 sites across 1 states
California1

Study leadership

  • Ajay Goel, PhD · PRINCIPAL_INVESTIGATOR · City of Hope Medical Center

Who to contact

Junyong Weng, PhD
[email protected]
06263151444
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Exclusion

other active malignancies; insufficient sample quality/volume; recent chemotherapy/radiotherapy/surgery; any condition preventing reliable participation.

What this trial measures

  • Diagnostic Accuracy of miRNA PanelAt baseline (pre-treatment blood sample).

    Sensitivity, specificity, and area under the receiver operating characteristic curve (AUROC) for distinguishing GI cancer patients from non-cancer controls.